This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MELA Sciences Names Rpr Marketing Communications As Its New Agency Of Record

NEW YORK, Jan. 3, 2013 /PRNewswire/ --  MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that developed MelaFind®, a breakthrough device intended to help dermatologists detect melanoma when it is still curable, announced today that it has named Rpr Marketing Communications as its U.S. public relations agency of record.

(Logo: )

"This partnership is a natural fit given both companies' unique expertise in skin cancer detection," said Joseph V. Gulfo, MD, President & CEO of MELA Sciences. "By driving awareness around melanoma detection, including the importance of annual mole checks and advanced diagnostic tools like MelaFind, we hope to help eradicate this deadly epidemic."

Rpr Marketing Communications will provide a full range of marketing communications based services, including consumer and professional media relations, corporate communications, professional meeting strategy and special initiative management. The New York City based agency has extensive experience within the aesthetic medicine, personal care and skincare industries, with proven success in the skin cancer awareness community.

"We planned to engage a marketing communications firm in the second half of our launch year to help us achieve our goals," said Dr. Gulfo.  "We chose Rpr after our search process because of their proven track record of widespread brand acceptance and adoption of products within our space.

Nearly one in five people are likely to get skin cancer this year. There are an estimated 130,000 new cases of melanoma diagnosed in the U.S. every year and according to the National Institutes of Health, 16 percent are diagnosed only after the disease has spread to other parts of the body. Nearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs